Vanda Pharmaceuticals (VNDA) announced the U.S. FDA has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide-based JAK2 inhibitor for the treatment of polycythemia vera, a form of a rare hematologic malignancy that is estimated to affect 1 in 2000 Americans.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals treatment of polycythemia vera granted orphan status
- Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
- Vanda Pharmaceuticals narrows 2024 revenue view to $190M-$210M from $180M-$210M
- Vanda Pharmaceuticals reports Q3 EPS (9c), consensus (16c)
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls